Positive Phase 2 and Mechanism-of-Action Data for BOLD-100 Presented at 2024 Metals in Medicine Gordon Research Conference
Bold Therapeutics has been invited to speak at the 2024 Metals in Medicine Gordon Research Conference.
Read more
Bold Therapeutics has been invited to speak at the 2024 Metals in Medicine Gordon Research Conference.
Read more
06-03-2024
Bold Therapeutics announced positive Phase 2 result for BOLD-100 in the treatment of advanced metastatic biliary tract cancer and gastric cancer at ASCO 2024.
04-04-2024
Bold Therapeutics announces that Dr. Do-Youn Oh’s group at Seoul National University College of Medicine will present at the AACR Meeting, April 5-10, 2024.
01-23-2024
Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024.
09-22-2023
Bold Therapeutics Selected as a 2023 Company to Watch by Life Sciences British Columbia (LSBC).
06-07-2023
Bold Therapeutics announced positive interim results in advanced gastric and biliary tract cancer at the 2023 ASCO Annual Meeting.
06-01-2023
Bold Therapeutics will be presenting positive interim results in advanced gastric and biliary tract cancer at 2023 (ASCO) Annual Meeting on June 2-6.
04-18-2023
Bold Therapeutics is excited to share interim Phase 2 data for BOLD-100 in the treatment of advanced colorectal cancer.
04-13-2023
Bold Therapeutics is excited to present robustly positive interim Phase 2 data in metastatic colorectal cancer at the upcoming AACR conference.
04-13-2023
Bold Therapeutics is excited to present robustly positive interim Phase 2 data in metastatic colorectal cancer at the upcoming AACR conference.
10-14-2022
Bold Therapeutics announces that they will be attending and presenting at BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences.
06-27-2022
Bold Therapeutics is excited to share compelling early efficacy data on BOLD-100 at the 2022 Metals in Medicine Gordon Research Conference.
05-10-2022
Bold Therapeutics is pleased to have been invited to present at Bio Korea 2022 as part of the Canadian trade delegation.
04-06-2022
Bold Therapeutics announced that it will present research supporting the use of BOLD-100 at the AACR Annual Meeting 2022 on April 8-13, 2022 in New Orleans.
04-04-2022
Bold Therapeutics is excited to announce second place in the Innovator’s Pitch Challenge at the Digital Redefining Early-Stage Investments Conference.
03-10-2022
Bold Therapeutics successfully completed Phase 1b of its oncology trial of BOLD-100 combined with FOLFOX in the treatment of advanced gastrointestinal cancers.
01-13-2022
Bold Therapeutics announces an extension of the option agreement with Hana Pharm for development and commercialization rights to BOLD-100 in South Korea.
09-16-2021
Bold Therapeutics has demonstrated potent anti-tumor activity in combination with a PD-1 checkpoint inhibitor in an in vivo model of colorectal cancer.
07-07-2021
Bold Therapeutics announces the addition of U.S. Sites for its phase 1b / 2a trial of BOLD-100 in the treatment of advanced GI cancers.
06-23-2021
Bold Therapeutics is pleased to be collaborating with Dr. Stephen Barr at Western University to study BOLD-100 in the COVID-19 variants of concern.
06-09-2020
Bold Therapeutics announces it is receiving additional funding of up to CAD$965,000 from NRC IRAP to support the development of BOLD-100 as a novel antiviral.